Journey Colab is unlocking the science of psychedelics to build a new model of addiction care combining the potential of neuroplasticity-promoting therapeutics with psychotherapy and community support. Our lead compound is synthetic Mescaline HCl for patients with alcohol use disorder (AUD), who are in desperate need of durable remission from this chronic, relapsing condition. Through our unique stakeholder structure, we have built an experienced team dedicated to our mission of creating scientifically rigorous and clinically validated treatments and improving equitable access to care.
Location: United States, California, San Francisco
Employees: 1-10
Total raised: $15.71M
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | MBX Capita... | mbxcapital... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.11.2021 | - | $15.71M | - |
Mentions in press and media 5
| Date | Title | Description |
| 19.02.2023 | ChatGPT creator Sam Altman has invested in dozens of companies over the years, from Elon Musk's Neuralink to Reddit | Sam Altman, CEO of OpenAI, has invested in scores of companies over the years. Kevin Dietsch/Getty Images OpenAI CEO Sam Altman has invested in lots of tech and energy companies. He was the lead investor in rounds for companies like Reddit,... |
| 25.07.2022 | Working with Indigenous allies is the ethical way to develop psychedelic-based pharmaceuticals | Psychedelic medicine is having a moment of tremendous growth and innovation as researchers rediscover its potential mental health benefits. Although numerous biopharmaceutical companies are aiming to capitalize on these age-old therapies, m... |
| 26.04.2022 | Mental Health Startup Journey Colab Aims To Develop Mescaline As An FDA-Approved Treatment For Alcohol Use Disorder | |
| 07.09.2021 | Journey Colab scores $12M to move psychedelics-based addiction treatment into clinic | Psychedelics-focused biotech Journey Colab bagged $12 million to start its first human trial in 2022. The funding will push its lead program, a treatment based on a hallucinogenic compound found in some species of cactus, into phase 1. The ... |
| 07.09.2021 | Journey Colab scores $12M to move psychedelics-based addiction treatment into clinic How to Optimize In Vitro and In Vivo Data Analysis and Data Management in Drug Research | Psychedelics-focused biotech Journey Colab bagged $12 million to start its first human trial in 2022. The funding will push its lead program, a treatment based on a hallucinogenic compound found in some species of cactus, into phase 1. RELA... |